Making a Case for the Socioeconomic Determinacy of Survival in Osteosarcoma
- 276 Downloads
The literature on osteosarcoma survival generally focuses on tumor and treatment variables, although it is unclear whether and how ethnic and socioeconomic factors might influence survival.
We therefore investigated the relative contribution of socioeconomic influences together with more traditional tumor-specific factors on osteosarcoma survival.
We performed survival analyses on two national databases in two countries. Using multivariable analyses, we compared these with corresponding institution-specific survival to determine if socioeconomic factors might impact osteosarcoma survival.
East Asian descent, state-specific treatment, female sex, treatment in the 1990s, low-grade disease, intracompartmental disease, small size, wide resections as opposed to forequarter or hindquarter amputations, and single primaries were good prognostic factors. Survival was better in the more affluent states. Males were affected at an older age than females. Blacks tended to have larger tumors, although their overall survival was similar to whites. East Asians were more likely to be treated in the 1990s with wide resections for smaller tumors and were located around states associated with good treatment. East Asians in Singapore and the United States had the same survival. Survival in East Asians in Singapore was similar to that of other races. The provision of health care for osteosarcoma varies greatly across the United States but is uniform in the socialized medical system in Singapore. Hence, the observed differences in the United States were likely the result of socioeconomic factors.
Our analysis suggests ethnic and economic bias may influence survival in osteosarcoma and should receive greater attention in the collective literature on survival analyses.
Level of Evidence
Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
KeywordsOsteosarcoma Wide Resection Major Amputation Affluent State Chondroblastic Osteosarcoma
We express our gratitude to Elyn R. Riedel, Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, for her invaluable assistance in statistical analysis.
- 2.Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, Adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198–206.PubMedGoogle Scholar
- 3.Bureau of Economic Analysis, US Department of Commerce; Per Capita Personal Income by State. Available at: http://bber.unm.edu/econ/us-pci.htm. 2004. Accessed November 25, 2004.
- 4.Enneking WF. Musculoskeletal Tumor Surgery. ed 1. New York, NY, USA: Churchill Livingstone; 1983.Google Scholar
- 7.Greene FL. AJCC Cancer Staging Manual. ed. 6. New York, NY, USA: Springer-Verlag; 2002.Google Scholar
- 8.Guo W, Xu W, Huvos AG, Healey JH, Feng C. Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl). 1999;112:1101–1104.Google Scholar
- 9.Huvos AG. Bone Tumors—Diagnosis, Treatment & Prognosis. ed. 2. Philadelphia, PA, USA: WB Saunders Co; 1991.Google Scholar
- 12.Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. Philadelphia, PA, USA: Lea & Febiger; 1958.Google Scholar
- 22.The Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute. Available at: http://seer.cancer.gov. 2004. Accessed November 18, 2004.
- 23.US Cancer Statistics Working Group. United States Cancer Statistics: 2000 Incidence and Mortality. Atlanta, GA, USA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2000.Google Scholar